BBHC
INSY

Brown Brothers Harriman & Co’s Insys Therapeutics, Inc. INSY Stock Holding History

Brown Brothers Harriman & Co’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,765
Closed -$36K – 1239
2017
Q4 		$36K Buy
+3,765
New +$24.6K ﹤0.01% 556

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brown Brothers Harriman & Co's INSY Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 3,765 shares — an estimated $36K sold.

Brown Brothers Harriman & Co first reported a position in INSY in Q4 2017 and held it in 1 quarter. The position peaked at $36K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 3,765 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $36K.
  • Brown Brothers Harriman & Co first reported a position in Insys Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Insys Therapeutics, Inc. position peaked at $36K in Q4 2017.
  • 110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.